Member Info for shatter

Investors cheered the capital raising initiative, which valued Symphony Environmental’s shares at a premium, making the dilution of existing shareholders more manageable given the rally.

From a technical perspective, Symphony shares could not break above the 28.55p resistance level despite the new shares being sold at 30p each, indicating that sellers were willing to jump in and defend the level.

However, I believe that there is a good chance the shares will break above the level due to the warrants issued to Miss Lophia, which are priced at a significant exercise premium of 40p each. Investors looking to capitalise on such a move higher should look out for potential entries at current levels.

Time will tell !

Vincel obviously sees a future with Sym. As Ctw said buying at a premium shows confidence. Just need a few contracts.

Well we know the reason for the recent drop now. It was merely to let Serum in at a good price.

Amazing set of results. The vaccine has been mostly responsible and is going to be needed in vast quantities for the foreseeable future ( unfortunately).I have a feeling that this is only going in one direction as profits continue to increase due to the pandemic.
The dilution is minimal thankfully and for a healthy wad of cash. I’m just going to sit on my hands and see where this goes. G.l whatever you decide

Hard to know if it’s the general market dragging this down or as Pooroldman says the results have already been built in and then some ! The sp has had guide a run recently. Not long to wait. G.l all

Morning all.. Oxb has got to be making money on the vaccines! As Kern says we have never seen a leak here so up 4% and down 6% is back to the good old days. The results shouldn’t throw up any nasty surprises otherwise they would have been duty bound to inform their investors.

Is there news on the way? Reasonable volume and a 4% rise..

Definitely treading water here. Back to the teens in the coming weeks. Sales team need a rocket up them…

Is it time to take a further look at Aviva PLC (LSE:AV.) (LON:AV.), the insurer that has started to splash the cash?

According to the highly respected financials team at Deutsche Bank (NYSE:DB), absolutely yes it is – notwithstanding the 32% total return investors have seen in the year to date.

In the wake of the recent numbers, Aviva has provided “reassurance and clarity”, according to Deutsche, which remains a ‘buyer’ of the stock up to 500p (current price 420p).

Its analysts were heartened by the £4bn capital return pledged by mid-2022 and the assurance the figure was “floor not a ceiling”.

That capital return is kicking off with a £750mln stock repurchase scheme.

Details on the rest of the cash return pledge will be unveiled in the group’s full-year results.

The interim results last week were a mixed bag. However, there was nothing in them that deterred the Deutsche number crunchers.

In July they stated “Symphony's legal team has accordingly filed Replies to each of the Defences, but a decision by the court is not expected for another 12-18 months.”
Sooo… you can probably double that…

Packaging worth 20 billion alone in America.

Packaging is a huge market. Once the sales start rolling in over the coming months the sky’s the limit.

Continuing in the right direction and making money..

Hi Jackdaw. I suspect America being the home of Capitalism has an agenda. As you say they have more than enough vaccines primarily using the Johnston and Johnston vaccine so why let an outsider in on the action. If Astra produced a cure all cough sweet in the morning they would still find a reason not to use it! A lot of people are making a lot of money from this pandemic. It brings out the worst in human nature. Yep, can only see upside in the share price.

Hey Kern.
Hope you are also well. With some ups and downs OXB can only go from strength to strength as it is basically a manufacturer with its products in demand. Very fortunate to be sitting with a free holding here. Have bought and sold very little recently. Seem to have the knack of dealing at the wrong time . Buy high and sell low. Sar on my watch list for years but never bought. Seems to be having a bad day but nothing ventured nothing gained. Hope it takes off. GL.

Slow and steady..

What’s that about 170million shares to be cancelled ? Not going to make a lot of difference in the grand scheme of things. Results are very encouraging.

Bottom of the life Insurance sector risers this morning.

The manufacturing agreement is for an initial five-year term and Meditech has stated its ambition that all gloves manufactured by it will be made with d2p anti-microbial and d2w oxo-biodegradable technology before 2024, the AIM-listed firm noted.

The supply will be exclusive if production reaches 100mln gloves per year.

Aviva need to get their finger out and make a decision. They know exactly what they have from their sales so how hard can it be to disseminate it whether it be by a Divi or share buy back.